Imperial College London, Hammersmith Hospital
London, W12 0NN, United Kingdom
NCT Number: NCT00912197
This study seeks to look into the effects of oligofructose supplementation on appetite, energy intake, and body weight and body composition in overweight subjects. Compared to a placebo product (cellulose) oligofructose is hypothesised to suppress hunger and thereby reduce food intake moderately leading to a decrease in body weight.
Looking for future studies?
Notify Me20 year–50 year
All sexes
Interventional
Not applicable
London, W12 0NN, United Kingdom
Appetite regulation plays an important part in energy balance. Suppressing appetite by manipulating the diet is a safe way of reducing energy intake and body weight compared to drug therapy and obesity surgery. How various nutrients affect appetite is not fully understood. Non-digestible carbohydrates (NDC) may affect appetite differently due to differences in physio-chemical properties.
This project will look into how two different NDC affect appetite and energy intake in overweight individuals in a randomised, double-blinded, placebo controlled parallel study. The NDC under investigation are oligofructose and cellulose, both natural compounds of plant origin. The former is broken down (fermented) in the large bowel by friendly bacteria producing various compounds that may affect appetite and the metabolism of the host.
Volunteers will consume one of the two NDC for eight weeks (including a two week run-in period). Appetite study session, functional MRI (fMRI) and MRI body fat scans will be conducted before and after the supplementation with NDC (or during the supplementation in the case of fMRI). Using fMRI the effect of the NDC supplementation on central appetite regulating centres will be investigated. Appetite questionnaires and dietary records will completed under free-living conditions at baseline and during the supplementation to explore the effect on subjective appetite feelings and energy intake, respectively.
It is hoped that this project will enhance the understanding of how NDC affect appetite and provide further information on how fermentation of NDC, gut hormone release, body composition, and appetite regulation are linked.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will be asked to consume 30g of oligofructose daily for six weeks after a 2-week run-in.
Participants will be asked to consume 3 doses (a total of 30g dietary fibres) of the placebo product daily for six weeks after a 2-week run-in
Time frame: Baseline, 56 days
Hunger was assessed by visual analogue scales (Each scale is 10cm in length with words anchored at each end, expressing the most positive (Minimum score = 0 cm and means no hunger) and the most negative rating (Maximum score = 10 cm and means very hungry). Compared to baseline after treatment at 56 days
Time frame: Baseline, 56 days
Fullness are assessed by visual analogue scale, 10 cm in length with words anchored at each end, expressing the most positive (feel full: maximum Score=10cm) and the most negative rating (feeling empty: Minimum Score = 0cm), values at baseline and after treatments at 56 days
Time frame: Baseline, 56 days
Time frame: Baseline, 56 days
Energy intake was assessed by 7-days food diary at baseline and last week of treatment, diaries were analysed by Dietplan6 software.
The values in the table represent the Energy intake as measured over the whole week (as opposed to reporting the Energy intake per day based on the 7 day data).
Time frame: baseline (Day 0) and post-supplementation (Day 56)
Total PYY concentrations were quantified using specific and sensitive in-house radio-immunoassays as previously described.
Time frame: Baseline, 56 days
Body composition assessed by BMI
Time frame: Baseline, 56 days
Total adipose tissue was assessed by FMRI at baseline and after treatment period
Time frame: Baseline, 56 days
Short-chain fatty acids (acetate, propionate, butyrate) concentrations assessed from plasma at 56 days at 450min timepoint with gas chromatography
Time frame: baseline (Day 0) and post-supplementation (Day 56)
No data were collected for this Outcome Measure
Time frame: baseline (Day 0) and post-supplementation (Day 56)
Glucose was analyzed in the Department of Clinical Biochemistry, Hammer-smith Hospital, London using an Abbott Architect ci8200 analyzer(Abbott Diagnostics, Maidenhead, UK).
Time frame: baseline (Day 0) and post-supplementation (Day 56)
Plasma insulin concentrations were assayed using RIA kits (Millipore, MO).
Time frame: baseline (Day 0) and post-supplementation (Day 56)
breath hydrogen were obtained from volunteers throughout the study session.
Imperial College London
Other
Effect of Oligofructose on Appetite, Gut Hormones and Body Composition in Healthy Overweight Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07444177
Appetite Regulation, Behavior
Seoul, South Korea
View Trial DetailsNCT07066618
Appetite Regulation, Body Weight
Sakarya, Turkey (Türkiye)
View Trial DetailsNCT01259895
Appetite Regulation, Body Weight
São Paulo, Brazil
View Trial DetailsNCT01240018
Appetite Regulation, Body Weight
Frederiksberg, DK, Denmark
View Trial Details